Form 4: Catheter Precision Executive Granted Stock Options
SEC Form 4
Marie-Claude Jacques, Chief Commercial Officer of Catheter Precision, Inc., reports the acquisition of stock options.
Summary
- Marie-Claude Jacques, the Chief Commercial Officer of Catheter Precision, Inc. (VTAK), filed a Form 4 on January 31, 2025.
- The filing reports the grant of stock options on January 29, 2025.
- Jacques acquired 125,000 stock options with an exercise price of $0.42.
- The options become exercisable in five tranches of 20% each, starting on January 29, 2025, and continuing annually until January 29, 2029.
- The options expire on January 29, 2035.
- Following the transaction, Jacques directly owns 125,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the medical device industry.
- The vesting schedule of 20% per year over five years is a fairly standard vesting schedule.
- Comparing the size of the grant to similar companies and executive roles would provide further context on the competitiveness of the compensation package.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of earliest transaction (grant of stock options) |
| 01/29/2025 | First vesting date of the stock options (20%) |
| 01/29/2026 | Second vesting date of the stock options (20%) |
| 01/29/2027 | Third vesting date of the stock options (20%) |
| 01/29/2028 | Fourth vesting date of the stock options (20%) |
| 01/29/2029 | Fifth vesting date of the stock options (20%) |
| 01/29/2035 | Expiration date of the stock options |
| 01/31/2025 | Date of Form 4 filing |
Keywords
Stock Options, Form 4, VTAK, Catheter Precision, Executive Compensation, Insider Transaction, Marie-Claude Jacques, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.